Skip to main content

Clinical Trials Terminated or Suspended by Chia Tai-Tianqing

 Due to the pharmaceutical industry's cold spell, an increasing number of enterprises are facing insufficient cash flow to support a multitude of clinical trials. Consequently, there is a rising trend of termination of clinical trials. It is well-known that the collaboration between CTTQ and Wuxi Apptec is very close. 

Here we summarize the clinical trials terminated or suspended by Chia Tai-Tianqing:

1. TQB3015 for cancer: ATR inhibitor

CTR20233919: phase 1 trial suspended without explanation

Initiated in 2023.12.05, suspended in 2023.12.19

2. TQC3564 for asthma: CRTH2 antagonist

CTR20220230: phase 1b study terminated as strategy adjustment

Initiated in 2022.1.29, terminated in 2023.5.9

3. TQC3564 for allergic rhinitisCRTH2 antagonist

CTR20220964: phase 1b study terminated as strategy adjustment

Initiated in 2022.8.17, terminated in 2023.5.9

4. TQB3823 for cancer: PARP inhibitor

CTR20211789: phase 1 trial terminated as strategy adjustment

Initiated in 2021.9.14, terminated in 2023.7.1

5. TQ-B3525 for CLL/SLL: PI3Kα/δ inhibitor

CTR20202705: phase 1b/2 trial  terminated as strategy adjustment

Initiated in 2021.5.24, terminated in 2023.11.22

6. TQ-B3525 for MCLPI3Kα/δ inhibitor

CTR20200773: phase 2 trial terminated as strategy adjustment

Initiated in 2020.7.1, suspended in 2023.10.10

7. TQ-B3139 for NSCLC: ALK/ROS1 inhibitor

CTR20220230: phase 2 study terminated as slow patient enrollment (34 pts enrolled since 2020)

Initiated in 2020.8.4, terminated in 2022.3.28

8. TQ-B3139 for NSCLC: ALK/ROS1 inhibitor

CTR20200428: phase 2 study terminated as slow patient enrollment

Initiated in 2019.8.21, terminated in 2023.10.24

9. TQB3602 for MM: proteasome inhibitor

CTR20200258: phase 1 trial  terminated as a commercial decision

Initiated in 2020.5.13, terminated in 2023.7.17

10. TQB34559 for blood cancer: IDH2 inhibitor

CTR20192368: phase 1 study terminated as slow patient enrollment (1 pt enrolled since 2020)

Initiated in 2020.3.25, terminated in 2021.3.15

11. Unecritinib (TQ-B3101) for NSCLC: ALK/ROS1/MET inhibitor

CTR20223411: phase 3 trial terminated as strategy adjustment

Initiated in 2023.1.10, terminated in 2023.6.26

12. Unecritinib (TQ-B3101) for cancer: ALK/ROS1/MET inhibitor

CTR20210926: phase 2 trial terminated as a slow progression

Initiated in 2021.9.28, terminated in 2023.10.26

13. TQB2858 for cancer: anti-PD-L1/TGF-β antibody

CTR20212102: phase 1 trial  terminated as a slow progression

Initiated in 2021.11.2, terminated in 2022.9.7

14. TQB2858 for pancreatic cancer: anti-PD-L1/TGF-β antibody

CTR20213454: phase 1 trial  terminated as pipeline adjustment

Initiated in 2022.2.23, terminated in 2023.8.23

15. TQB2858 for soft tissue sarcoma: anti-PD-L1/TGF-β antibody

CTR20213001: phase 1 trial  terminated as reference BsAbs clinical results consideration

Initiated in 2021.11.22, terminated in 2023.2.7

16. TQB2858 for cervical cancer: anti-PD-L1/TGF-β antibody

CTR20212698: phase 1 trial  terminated as reference BsAbs clinical results consideration

Initiated in 2022.1.13, terminated in 2022.9.9

17. TQB3820 for blood cancer: Aiolos/Ikaros degrader

CTR20211930: phase 1 study terminated as not meeting the expectation

Initiated in 2021.8.25, terminated in 2023.10.18

18. TQH3910 for PsA: Undisclosed

CTR20221197: phase 1 study terminated as strategy adjustment

Initiated in 2022.6.9, terminated in 2022.11.18

19. TQ05105 for myelofibrosis: JAK1/2 and ROCK1/2 inhibitor

CTR20220784: phase 1b trial terminated as a slow progression

Initiated in 2022.7.14, terminated in 2023.10.8

20. TQ05105 for aGVHD: JAK1/2 and ROCK1/2 inhibitor

CTR20211289: phase 1 trial terminated as a slow progression

Initiated in 2022.6.10, terminated in 2023.6.15

21. TQB2450 for cholangiocarcinoma: anti-PD-L1 antibody

CTR20212456: phase 3 study terminated as competition and commercial reason

Initiated in 2021.1.26, terminated in 2023.2.1

22. TQB2450 for HNSCC: anti-PD-L1 antibody

CTR20190292: phase 3 study terminated as strategy adjustment

Initiated in 20219.7.8, terminated in 2023.8.10

23. TQB3824 for cancer: CDC7 inhibitor

CTR20211918: phase 1 study terminated as strategy adjustment

Initiated in 2021.8.19, terminated in 2023.8.16

24. TQ05105 for myelofibrosis: JAK1/2 and ROCK1/2 inhibitor

CTR20211289: phase 1b trial terminated as a slow progression

Initiated in 2022.7.14, terminated in 2023.10.8

25. TQ05510 for type 2 diabetes: DPP4 inhibitor

CTR20201230: phase 1b study terminated as efficacy consideration

Initiated in 2020.8.5, terminated in 2021.1.20

26. TQB3303 for solid tumors: CDK4/6 inhibitor

CTR20211289: phase 1b trial terminated as a strategy adjustment

Initiated in 2020.9.14, terminated in 2023.8.20

27. Anlotinib for gastric and adenocarcinoma of esophagogastric junction cancer: VEGFR-1/2/3 inhibitor

CTR20200753: phase 3 study terminated as a slow progression

Initiated in 2020.8.10, terminated in 2023.12.10

28. TQB3473 for blood cancer: SYK inhibitor

CTR20200666: phase 1 trial terminated as a strategy adjustment

Initiated in 2020.9.10, terminated in 2023.6.30

29. TQB3562 for solid tumors: IDO inhibitor

CTR20200427: phase 1 trial terminated as a strategy adjustment

Initiated in 2020.6.2, terminated in 2023.7.19

30. AL2846 for NSCLC with bone mets: c-MET inhibitor

CTR20200413: phase 2 trial terminated as difficult to obtain clinical endpoints

Initiated in 2020.9.8, terminated in 2020.11.13

31. TQB3456 for NSCLC: EGFR inhibitor

CTR20181470: phase 1 trial terminated as strategy adjustment

Initiated in 2018.7.20, terminated in 2020.10.10

32. TQB2868 for cervical cancer: anti-PD-1/TGF-β antibody

NCT05998941: phase 2 trial withdrawal as a slow progression (phase 1 study ongoing)

Initiated in 203.8.21, terminated in 2023.11.20

Comments